Xilio Therapeutics Inc
XLO
查看详细走势图
0.669USD
+0.019+2.92%
收盘 12/19, 16:00（美东）报价延迟15分钟
34.67M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.92%
5天
-1.78%
1月
-10.80%
6月
-2.83%
今年开始到现在
-29.95%
1年
-47.73%
查看详细走势图
TradingKey Xilio Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Xilio Therapeutics Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名104/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价2.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Xilio Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
强力买入
评级
2.000
目标均价
+173.97%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Xilio Therapeutics Inc亮点
亮点风险
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
业绩增长期
公司处于发展阶段，最新年度总收入6.34M美元
估值低估
公司最新PE估值-1.09，处于3年历史低位
机构减仓
最新机构持股13.13M股，环比减少32.58%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值204.70K
Xilio Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Xilio Therapeutics Inc简介
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
公司代码XLO
公司Xilio Therapeutics Inc
CEORusso (Rene)
网址https://xiliotx.com/
常见问题
Xilio Therapeutics Inc(XLO)的当前股价是多少？
Xilio Therapeutics Inc(XLO)的当前股价是 0.669。
Xilio Therapeutics Inc的股票代码是什么？
Xilio Therapeutics Inc的股票代码是XLO。
Xilio Therapeutics Inc股票的52周最高点是多少？
Xilio Therapeutics Inc股票的52周最高点是1.700。
Xilio Therapeutics Inc股票的52周最低点是多少？
Xilio Therapeutics Inc股票的52周最低点是0.615。
Xilio Therapeutics Inc的市值是多少？
Xilio Therapeutics Inc的市值是34.67M。
Xilio Therapeutics Inc的净利润是多少？
Xilio Therapeutics Inc的净利润为-58.24M。
现在Xilio Therapeutics Inc(XLO)的股票是买入、持有还是卖出？
根据分析师评级，Xilio Therapeutics Inc(XLO)的总体评级为--，目标价格为2.000。
Xilio Therapeutics Inc(XLO)股票的每股收益（EPS TTM）是多少
Xilio Therapeutics Inc(XLO)股票的每股收益（EPS TTM）是-0.612。
相关品种
